Idorsia

Idorsia, a pharmaceutical preparation manufacturing company headquartered in Switzerland (CH), has reported significant carbon emissions across Scopes 1, 2, and 3. For the reporting year 2024, Idorsia's total global greenhouse gas emissions amounted to approximately 73.04 million kg CO2e. This figure is comprised of about 733,400 kg CO2e for Scope 1 emissions and approximately 29,200 kg CO2e for Scope 2 emissions. Scope 3 emissions for 2024 were reported at approximately 68.49 million kg CO2e, though specific upstream categories like purchased goods and services were noted as missing data points.

In 2023, Idorsia's emissions totalled approximately 982,800 kg CO2e, with Scope 1 emissions at about 475,000 kg CO2e and Scope 2 emissions at approximately 507,800 kg CO2e. Scope 3 data was not disclosed for this year. Prior to this, in 2022, total emissions were around 813,200 kg CO2e, comprising 413,200 kg CO2e for Scope 1 and 400,000 kg CO2e for Scope 2. In 2021, total emissions were approximately 952,300 kg CO2e, with Scope 1 at 532,100 kg CO2e and Scope 2 at 420,200 kg CO2e.

Idorsia has set ambitious climate commitments to reduce its environmental impact. Notably, the company aims to achieve a reduction of its greenhouse gas emissions (Scope 1 and 2) by approximately 50% by 2030, using 2024 as a baseline year. This commitment is supported by initiatives expected to drive this reduction. While specific overarching reduction targets for all scopes are in place, the reporting for Scope 3 emissions in earlier years was not comprehensive. Idorsia's climate strategy focuses on emission reduction efforts within its operational boundaries.